Literature DB >> 367155

A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma.

S S Schwarts, A Zeidler, A R Moossa, S F Kuku, A H Rubenstein.   

Abstract

Ninety-nine patients suspected of having pancreatic carcinoma were studied prospectively for carbohydrate tolerance. Thirty-two patients were proven subsequently to have pancreatic carcinoma; the remainder served as a control group. There was an increased incidence of carbohydrate intolerance in patients with pancreatic carcinoma compared to the control group. Insulin and C-peptide measurements during glucose tolerance tests suggest abnormal beta cell function and possibly insulin resistance as causes for this abnormality. Although factors related to malignancy in general could partly account for the results, a specific factor occurring in patients with pancreatic carcinoma must also be considered as it could serve as a marker for the early detection of this disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 367155     DOI: 10.1007/bf01072886

Source DB:  PubMed          Journal:  Am J Dig Dis        ISSN: 0002-9211


  14 in total

Review 1.  The glucose tolerance test: a pitfall in the diagnosis of diabetes mellitus.

Authors:  M D Siperstein
Journal:  Adv Intern Med       Date:  1975

2.  Abnormal carbohydrate metabolism in pancreatic carcinoma.

Authors:  R MURPHY; F H SMITH
Journal:  Med Clin North Am       Date:  1963-03       Impact factor: 5.456

3.  Diabetes mellitus and primary carcinoma of the pancreas.

Authors:  C G CLARK; P E MITCHELL
Journal:  Br Med J       Date:  1961-11-11

4.  Carcinoma of the pancreas. I. A clinical and pathologic study of 609 necropsied cases. II. The relation of carcinoma of the pancreas to diabetes mellitus.

Authors:  E T BELL
Journal:  Am J Pathol       Date:  1957 May-Jun       Impact factor: 4.307

5.  The association between carcinoma of the pancreas and diabetes mellitus.

Authors:  A J Karmody; J Kyle
Journal:  Br J Surg       Date:  1969-05       Impact factor: 6.939

Review 6.  Endocrine function in protein-calorie malnutrition.

Authors:  B Pimstone
Journal:  Clin Endocrinol (Oxf)       Date:  1976-01       Impact factor: 3.478

7.  Glucose intolerance during decreased physical activity in man.

Authors:  R L Lipman; P Raskin; T Love; J Triebwasser; F R Lecocq; J J Schnure
Journal:  Diabetes       Date:  1972-02       Impact factor: 9.461

8.  Heterogeneity of plasma glucagon: patterns in patients with chronic renal failure and diabetes.

Authors:  S F Kuku; A Zeidler; D S Emmanouel; A I Katz; A H Rubenstein
Journal:  J Clin Endocrinol Metab       Date:  1976-01       Impact factor: 5.958

Review 9.  Clinical significance of circulating proinsulin and C-peptide.

Authors:  A H Rubenstein; D F Steiner; D L Horwitz; M E Mako; M B Block; J I Starr; H Kuzuya; F Melani
Journal:  Recent Prog Horm Res       Date:  1976

10.  Identification of proinsulin and C-peptide in human serum by a specific immunoassay.

Authors:  F Melani; A H Rubenstein; P E Oyer; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

View more
  19 in total

1.  Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines.

Authors:  F Wang; J Larsson; A Abdiu; T Gasslander; P Westermark; T E Adrian; J Permert
Journal:  Int J Pancreatol       Date:  1997-04

2.  Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer.

Authors:  Katherine Y Fan; Avani S Dholakia; Aaron T Wild; Zheng Su; Amy Hacker-Prietz; Rachit Kumar; Mary Hodgin; Charles C Hsu; Dung T Le; Ana De Jesus-Acosta; Luis A Diaz; Daniel A Laheru; Ralph H Hruban; Elliot K Fishman; Todd D Brown; Timothy M Pawlik; Christopher L Wolfgang; Phuoc T Tran; Joseph M Herman
Journal:  J Natl Compr Canc Netw       Date:  2014-01       Impact factor: 11.908

Review 3.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

Review 4.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

5.  The specificity of amylin for the diagnosis of pancreatic adenocarcinoma.

Authors:  Randall E Brand; Xian-Zhong Ding; Christine M Young; Thomas E Adrian
Journal:  Int J Gastrointest Cancer       Date:  2002

6.  Diabetes and pancreatic cancer.

Authors:  A Schattner
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-02

7.  The place of total and extended total pancreatectomy in pancreatic cancer.

Authors:  A R Moossa; M H Scott; M Lavelle-Jones
Journal:  World J Surg       Date:  1984-12       Impact factor: 3.352

Review 8.  Diabetes mellitus: a risk factor for pancreatic cancer?

Authors:  M Yalniz; P M Pour
Journal:  Langenbecks Arch Surg       Date:  2004-04-09       Impact factor: 3.445

9.  Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice.

Authors:  Gaurav Aggarwal; Vijaya Ramachandran; Naureen Javeed; Thiruvengadam Arumugam; Shamit Dutta; George G Klee; Eric W Klee; Thomas C Smyrk; William Bamlet; Jing Jing Han; Natalia B Rumie Vittar; Mariza de Andrade; Debabrata Mukhopadhyay; Gloria M Petersen; Martin E Fernandez-Zapico; Craig D Logsdon; Suresh T Chari
Journal:  Gastroenterology       Date:  2012-09-06       Impact factor: 22.682

10.  Prospective evaluation of some candidate tumor markers in the diagnosis of pancreatic cancer.

Authors:  C R Mackie; A R Moossa; V L Go; G Noble; G Sizemore; M J Cooper; R A Wood; A W Hall; T Waldmann; F Gelder; A H Rubenstein
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.